ArticleJournal of gynecologic oncology2025

Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis.

Lin Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.